Strategic Partnerships Sensome’s Clotild Smart Guidewire system, developed in collaboration with Asahi Intecc and integrated with Robocath robotic systems, signals strong partner-led sales potential in interventional cardiology and neurovascular markets. Leverage existing OEM relationships to position bundled solutions for stroke treatment and clot management.

Clinical Validation Recent proof-of-concept deployments with Robocath and Robotic systems validate real-time tissue analysis capability during procedures. Use these case studies to build credibility with hospitals seeking evidence-backed, intraoperative decision support to improve outcomes in stroke and cancer biopsy contexts.

Regulatory Readiness With EN ISO 13485:2016 certification, Sensome demonstrates a quality management framework suitable for medical device manufacturing and clinical adoption. Market opportunities can be accelerated by targeting high-volume centers that require ISO-aligned suppliers for device integration and audits.

Technology Positioning World’s smallest impedance-based sensor enabling 360° tissue characterization positions Sensome for integration into a range of guidewires and ancillary devices. Sales plays can target vascular interventions, oncology biopsy workflows, and neurovascular procedures seeking real-time tissue characterization.

Funding & Growth With significant funding secured and ongoing collaboration with leading manufacturers, Sensome’s growth trajectory supports joint go-to-market initiatives. Propose co-marketing, grant-backed deployments, and expansion into international markets where robotic-assisted interventions are expanding.